Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics Limited (AU:PER)
:PER
PER Stock Chart & Stats
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.14
Previous CloseN/A
Volume20.44M
Average Volume (3M)7.94M
Market Cap
AU$15.22M
Enterprise ValueAU$39.35M
Total Cash (Recent Filing)1.90M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 27, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,087,437,600
10 Day Avg. Volume13,339,766
30 Day Avg. Volume7,938,777
Standard Deviation0.23
R-Squared0.02
Alpha0.00281
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)112.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.02Price Target Upside56.42% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Percheron Therapeutics News
PremiumCompany Announcements
Powerhouse Ventures Increases Stake in Percheron Therapeutics
PremiumCompany Announcements
Percheron Therapeutics Aims to Rebound with New Drug Opportunities
PremiumCompany Announcements
Percheron Therapeutics to Present Promising Phase IIb Trial Results
PremiumCompany Announcements
Percheron Therapeutics Announces Cessation of Securities
PremiumCompany Announcements
Percheron Therapeutics Reassesses Strategy Following Avicursen Study OutcomePremiumCompany Announcements
Percheron Therapeutics Directors Oppose Shareholder ResolutionsPremiumCompany Announcements
Powerhouse Ventures Increases Stake in Percheron Therapeutics
PremiumCompany Announcements
Change in Substantial Holding for Percheron Therapeutics---
Options Prices
Currently, No data available
---
Ownership Overview
PER FAQ
What was Percheron Therapeutics Limited’s price range in the past 12 months?
Percheron Therapeutics Limited lowest share price was <AU$0.01 and its highest was AU$0.14 in the past 12 months.
What is Percheron Therapeutics Limited’s market cap?
Percheron Therapeutics Limited’s market cap is AU$15.22M.
When is Percheron Therapeutics Limited’s upcoming earnings report date?
Percheron Therapeutics Limited’s upcoming earnings report date is Aug 27, 2025 which is in 186 days.
How were Percheron Therapeutics Limited’s earnings last quarter?
Percheron Therapeutics Limited released its earnings results on Feb 19, 2025. The company reported -AU$0.009 earnings per share for the quarter, beating the consensus estimate of -AU$0.015 by AU$0.006.
Is Percheron Therapeutics Limited overvalued?
According to Wall Street analysts Percheron Therapeutics Limited’s price is currently Undervalued.
Does Percheron Therapeutics Limited pay dividends?
Percheron Therapeutics Limited does not currently pay dividends.
What is Percheron Therapeutics Limited’s EPS estimate?
Percheron Therapeutics Limited’s EPS estimate is -0.02.
How many shares outstanding does Percheron Therapeutics Limited have?
Percheron Therapeutics Limited has 1,087,437,600 shares outstanding.
What happened to Percheron Therapeutics Limited’s price movement after its last earnings report?
Percheron Therapeutics Limited reported an EPS of -AU$0.009 in its last earnings report, beating expectations of -AU$0.015. Following the earnings report the stock price went up 2.439%.
Which hedge fund is a major shareholder of Percheron Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PER
---
Percheron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.02 (56.42% Upside)
AU$0.02 (56.42% Upside)
Blogger Sentiment
Bullish
AU:PER Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $21.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
660.00%
12-Months-Change
Fundamentals
Return on Equity
-100.19%
Trailing 12-Months
Asset Growth
-18.60%
Trailing 12-Months
Company Description
Percheron Therapeutics Limited
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded in November 13, 2000 and is headquartered in Toorak, Australia.
---
PER Stock 12 Month Forecast
Average Price Target
AU$0.02
▲(56.42% Upside)
Technical Analysis
Cochlear Limited
―
Opthea Limited
―
CSL
―
Nanosonics Limited
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Best Analysts Covering PER
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-42.15%
reiterated a buy rating 6 months ago
Copying Iain Wilkie's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.15% per trade.
---